Covalent Modification of the JH2 Domain of Janus Kinase 2. [PDF]
ACS Med Chem Lett, 2022 Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to evaluate JH2 domains as therapeutic targets. The JH2 domains of three Janus kinases (JAK1, JAK2, and TYK2) possess a cysteine residue in the catalytic ...
Henry SP +6 more
europepmc +3 more sources
The prolactin receptor scaffolds Janus kinase 2 via co-structure formation with phosphoinositide-4,5-bisphosphate [PDF]
eLife, 2023 Class 1 cytokine receptors transmit signals through the membrane by a single transmembrane helix to an intrinsically disordered cytoplasmic domain that lacks kinase activity. While specific binding to phosphoinositides has been reported for the prolactin
Raul Araya-Secchi +8 more
doaj +2 more sources
-escin mitigates neuroinflammation and apoptosis caused by ischemic stroke through the inhibition of the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway [PDF]
Journal of International Medical ResearchObjective This study aimed to investigate the protective effects of β-escin against neuroinflammatory injury and its influence on the interleukin-6/Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of ...
Duan Yanqin +9 more
doaj +2 more sources
Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]
Postgraduate Medicine, 2013 Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
Srdan Verstovšek
exaly +3 more sources
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
Journal of Experimental Pharmacology, 2016 Jack W Singer,1 Suliman Al-Fayoumi,1 Haiching Ma,2 Rami S Komrokji,3 Ruben Mesa,4 Srdan Verstovsek5 1Translational Medicine, CTI BioPharma Corp., Seattle, WA, 2Department of Research and Development, Reaction Biology, Malvern, PA, 3Department of ...
Singer J +5 more
doaj +4 more sources
Frontiers in Medicine, 2023 Aberrant activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is common in systemic lupus erythematosus (SLE), conferring immune-mediated properties in target tissues.
Dionysis Nikolopoulos +4 more
doaj +3 more sources
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm [PDF]
South Asian Journal of Cancer, 2017 Context: Alterations in megakaryocyte morphology are the hallmark of myeloproliferative neoplasms (MPNs). These neoplasm are also associated with Janus kinase 2 (JAK2) V617F mutation in nearly 95% patients with polycythemia vera (PV), 40% patients of ...
Shuchi Ghai, Sharada Rai
doaj +3 more sources
Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor [PDF]
Tzu Chi Medical Journal, 2019 Polycythemia vera (PV) is relatively uncommon in early adulthood, and evidence about the prevalence of the Janus kinase 2 (JAK2) V617F mutation in the general population is limited.
Shang-Hsien Yang +3 more
doaj +2 more sources
Janus kinase inhibitors - their current applications and future prospects [PDF]
Farmacja Polska, 2022 Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska +4 more
doaj +1 more source
Itch and Janus Kinase Inhibitors
Acta Dermato-Venereologica, 2023 Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han +4 more
doaj +1 more source